Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 9/20 | 0.51 |
| ▸ | SI | P14410 | 6/20 | 0.51 |
| ▸ | AMY2A | P04746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | GLB1 | P16278 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salbostatin SCHEMBL14408644 | 1.00 | TREH (1.00) | TREHMGAMSIAMY2AGAA | |
| Salbostatin SCHEMBL12094885 | 1.00 | TREH (1.00) | TREHMGAMSIAMY2AGAA | |
| SCHEMBL14408591 | 0.75 | MGAM (0.65) | TREHMGAMSIAMY2AGAA | |
| SCHEMBL10033385 | 0.75 | MGAM (0.65) | TREHMGAMSIAMY2AGAA | |
| Validoxylamine A SCHEMBL29375116 | 0.75 | TREH (0.60) | TREHMGAMSIAMY2AGBA1 | |
| Validoxylamine A SCHEMBL5160235 | 0.75 | TREH (0.60) | TREHMGAMSIAMY2AGBA1 | |
| SCHEMBL14408705 | 0.75 | MGAM (0.63) | TREHMGAMSIAMY2AGAA | |
| SCHEMBL14408901 | 0.73 | MGAM (0.72) | TREHMGAMSIAMY2AGAA | |
| SCHEMBL14408573 | 0.73 | TREH (0.57) | TREHMGAMSIAMY2AGAA | |
| Validamycin SCHEMBL3121491 | 0.72 | AMY2A (0.56) | TREHMGAMSIAMY2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5643874-A | ANTIOBESITY AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-01 | — | — | US | claimed |
| US-20250134923-A1 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | JUNION LABS PTE. LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| CN-116509842-B | Pharmaceutical composition, preparation method and application thereof | 厦门君德医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-4392044-A2 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | Junion Labs Pte. Ltd. (SG) | 2024-07-03 | — | — | EP | disclosed |
| CN-116509842-A | Pharmaceutical composition, preparation method and application thereof | 厦门君德医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116133656-A | Superabsorbent hydrogels containing lipase inhibitors | 君德(新加坡)实验室有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023038575-A2 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | JUNION LABS PTE. LTD. (SG) | 2023-03-16 | — | — | WO | disclosed |
| EP-1178846-B1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | PROCTER & GAMBLE (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090041740-A1 | CANCER TREATMENT BY METABOLIC MODULATIONS | ENGENE, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| EP-1227776-B1 | ABSORBENT ARTICLE HAVING BARRIER SHEET AGAINST THE MIGRATION OF THE SKIN CARE COMPOSITION | PROCTER & GAMBLE (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1227776-A1 | ABSORBENT ARTICLE HAVING BARRIER SHEET AGAINST THE MIGRATION OF THE SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1178845-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-13 | — | — | EP | disclosed |
| EP-1178846-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001024748-A1 | ABSORBENT ARTICLE HAVING BARRIER SHEET AGAINST THE MIGRATION OF THE SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000069482-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069481-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069483-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069484-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069485-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| US-5643874-A | ANTIOBESITY AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134923-A1 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | LCT, LIPE, MGLL | TREH 479/4885MGAM 9/4885SI 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.